In this  report an instance of COVID-19 in a patient with sarcoidosis who was getting long haul hydroxychloroquine treatment and contracted COVID-19 notwithstanding sufficient plasma focuses.

Due to in vitro considers recommending possible action on extreme intense respiratory condition Covid 2 (SARS-CoV-2) (1,2), hydroxychloroquine has been one of the primary competitor drugs assessed for Covid infection (COVID-19), both as a corrective therapy and as preexposure or postexposure prophylaxis. We report an instance of COVID-19 in a patient accepting long haul hydroxychloroquine treatment in spite of plasma fixations inside the helpful reach for immune system illnesses, for example, fundamental lupus erythematosus. A 40-year-elderly person was conceded to Pontchaillou University Hospital, Rennes, France, for treatment of COVID-19. His clinical history was surprising just for pneumonic sarcoidosis, analyzed in 2015; it was very much controlled with hydroxychloroquine (200 mg 2×/d) with no other immunomodulatory drugs and no adherence issues. Twelve days before affirmation, he had gotten an analysis of COVID-19 in the outpatient division following a 4-day course of hack, myalgia, and second rate fever. He had positive outcomes by PCR for SARS-CoV-2 on a nasopharyngeal.

Reference link-